DNA-targeting and cell-penetrating antibody-drug conjugate
Shirali, A.; Dubljevic, V.; Cao, F.; Nishimura, R. N.; Ebens, A.; Campbell, J. A.; Hansen, J. E.
Show abstract
DNA released by dying cancer cells offers a tumor targeting strategy that is independent of specific cell surface antigens. Anti-DNA antibodies preferentially localize to tumor microenvironments enriched in extracellular DNA and can penetrate live tumor cells through nucleoside salvage pathways. Nuclear-localizing variants of anti-DNA antibodies cause DNA damage and selectively kill cancer cells with defects in DNA repair. Here we show that an optimized full-length IgG1 anti-DNA antibody penetrates live cells and is synthetically lethal to BRCA2-deficient tumors but has minimal effect of DNA repair-proficient tumors. Linkage of the antibody to the anti-mitotic drug monomethyl auristatin E yields a DNA-targeting and cell-penetrating anti-DNA antibody-drug conjugate (ADC) that is well tolerated in mice and highly toxic to tumors with intact DNA repair. This work provides proof-of-concept for the novel use of an anti-DNA antibody as the backbone of a DNA-targeting, cell-penetrating ADC that can impact tumors that otherwise lack specifically targetable surface antigens. Statement of significanceA strategy for targeting tumors that lack specific surface antigens is revealed by an anti-DNA antibody-drug conjugate that localizes to tumor microenvironments enriched in DNA and penetrates cells through nucleoside salvage pathways.
Matching journals
The top 14 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancer 96%
- TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy 96%
- Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer 96%
Similar papers in this journal
- STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer 95%
- Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors 93%
- Ivermectin converts cold tumors hot and synergies with immune checkpoint blockade for treatment of breast cancer 92%
Similar papers in this journal
- SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected & Non-injected Lesions 94%
- Engineering living immunotherapeutic agents for improved cancer treatment 92%
- Targeting glioblastoma tumor hyaluronan to enhance therapeutic interventions that regulate metabolic cell properties 90%
Similar papers in this journal
- Overcoming Tumor Heterogeneity by Ex Vivo Arming of T Cells Using Multiple Bispecific Antibodies 95%
- Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation Therapy 93%
- Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma 92%
Similar papers in this journal
- A novel fully-human potency-matched dual cytokine-antibody fusion protein targets carbonic anhydrase IX in renal cell carcinomas 95%
- Modulated TRPC1 expression predicts sensitivity of breast cancer to doxorubicin and magnetic field therapy: segue towards a precision medicine approach. 94%
- High Affinity Chimeric Antigen Receptor with Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.